The companies said the drug vintafolide didn't slow the progress of ovarian cancer. The trial compared a combination of vintafolide and the chemotherapy drug doxorubicin to doxorubicin and a placebo, and it was designed to test whether patients who took vintafolide lived longer before the resumption of disease progression or deaths.
The patients in the study had ovarian cancer and had not been helped by platinum-based chemotherapy.
The companies are ending the trial based on advice from an independent committee that reviewed data from the study.
Vintafolide, or Vynfinit, is designed to target a receptor that appears on cancer cells but doesn't exist on most other cells. In
In early April,
Most Popular Stories
- 'Lucy's' Super Powers Tops 'Hercules' at Box Office
- The 2014 Fastest-Growing 100
- Vancrest Assisted Living Project to Add 20 Jobs
- The Rise and Fall of Richard Alarcon
- Fighting Blocks Investigators, Police From MH17 Crash Site
- Insecticides Permeate U.S. Food, Water Supply
- VW Site Could Mean Another 2,000 Jobs for Chattanooga
- Ford Bumps Price of New F-150
- Nissan Profits Rise on Growth in U.S., China
- U.N. Renews Demand for Gaza Cease-Fire